Studies suggest that people who are HIV-positive are less likely to receive cancer treatment than those who are HIV-negative. Anne Rositch, Ph.D., discusses why this "HIV effect" might exist.
Bone mineral density (BMD) declined significantly more in antiretroviral-treated U.S. study participants with HIV than in age-similar HIV-negative adults over seven years of follow-up.
Renal adverse events and fractures proved rare among people taking tenofovir disoproxil fumarate (TDF) as part of a single-tablet regimen in a large U.S. database of insured patients.
Bone mineral density (BMD) improved in the 96 weeks after patients switched from a combination containing tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) as part of the single-tablet regimen elvitegravir/cobicistat/emtricitabine/TA...
The burden that HIV places on women, particularly adolescent girls and young women from low- and middle-income countries, is compounded by the global burden of human papillomavirus (HPV) infection and cervical cancer.
A report from the PROMISE study showed no adverse bone mineral effect, linked to maternal tenofovir disoproxil fumarate (TDF), in exposed infants.
Researchers investigated using the combined ledipasvir/sofosbuvir for only six weeks in a small group of HIV-positive people diagnosed with acute hepatitis C.
While neurocognitive problems may appear very early on in acute HIV infection, "there is a profound misconception that HIV will affect the brain in everyone," says Bruce J. Brew, M.D., F.R.A.C.P.
Further research bolsters findings that HIV-positive people are at increased risk for developing osteopenia and osteoporosis and, in rare cases, osteonecrosis.
A small clinical trial found that a single infusion of zoledronic acid prevented ART-induced bone loss for one year.